FDA Inspection 1159830 — PAREXEL International GmbH
The FDA completed an inspection of PAREXEL International GmbH on Nov 12, 2021 in Berlin. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Nov 12, 2021
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Berlin (Germany)
Additional details
Clinical BA/BE